Abstract
INTRODUCTION
Severe aortic stenosis with symptoms or left ventricular dysfunction has a poor prognosis. In this scenario, aortic valve replacement (AVR) improves the functional class and survival rate [1] . However, until the last decade, a third of patients with severe aortic stenosis who required valve surgery were rejected due to their comorbid conditions and high surgical risk [2] .
Transcatheter aortic valve replacement (TAVR) is an alternative for this high-risk group [3] . TAVR has been shown to improve survival in inoperable patients compared with medical treatment or balloon valvuloplasty. Therefore, the 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease recommends TAVR as a level I indication for patients with aortic stenosis and prohibitive surgical risk [1] .
Nonetheless, in patients with moderate or high surgical risk, comparing TAVR with surgical aortic valve replacement (SAVR) has yielded conflicting results regarding early and late survival, risk of neurological damage and residual aortic regurgitation (RAR), among others. Although several randomized clinical trials and many observational studies have been published, there is a huge variability in their design, inclusion and exclusion criteria and definition of the events, which makes it difficult to draw clear, robust conclusions. Therefore, it is at the discretion of heart teams at each medical centre to decide on one or the other treatment. The available scientific evidence offers little to the decision-making process [4, 5] . Thus, the 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease recommends TAVR as an alternative to SAVR in patients at high risk and recommends that the decision on TAVR be made by consensus by a heart team [1] . For patients at intermediate risk, SAVR is still the preferred therapy.
The purpose of this meta-analysis was to compare early and late outcomes and haemodynamic performance of TAVR versus SAVR in patients with moderate or high risk for SAVR.
METHODS
This meta-analysis was performed according to the recommendations of the PRISMA statement [6] , the MOOSE [7] and the Cochrane Handbook for Systematic Reviews of Interventions [8] .
Data sources
We searched the National Library of Medicine's PubMed database, the Cochrane Central Register of clinical trials and the ISI Web of Science to identify clinical studies comparing mortality and major cerebrovascular events in patients who had TAVI and SAVR. We also searched conference proceedings from meetings of the European Association for Cardio-Thoracic Surgery, the European Society of Cardiology, the American Heart Association, the American College of Cardiology and the Society of Thoracic Surgeons. Related links of all relevant reports on PubMed were reviewed. In addition, we manually reviewed the reference lists of all retrieved reports to complete our search. Searches were restricted to English-language publications from January 2009 to June 2016. The key words used were ('sutureless' or 'SAVR' or 'surgical aortic valve replacement' or 'SuAVR') and ('TAVI' or 'TAVR' or 'transcatheter aortic valve replacement' or 'transcatheter aortic valve implantation' or 'trans-catheter aortic valve replacement' or 'trans-catheter aortic valve implantation' or 'trans-femoral aortic valve replacement' or 'trans-femoral aortic valve implantation' or 'trans-femoral aortic valve replacement' or 'trans-femoral aortic valve implantation' or 'transapical aortic valve implantation' or 'transapical aortic valve replacement' or 'trans-apical aortic valve implantation' or 'trans-apical aortic valve replacement' or 'transaortic valve implantation' or 'transaortic valve implantation' or 'trans-aortic valve replacement' or 'transaortic valve replacement' or 'trans-subclavian aortic valve replacement' or 'trans-subclavian aortic valve implantation' or 'transubclavian aortic valve replacement' or 'transubclavian aortic valve implantation'). Two different investigators conducted the search.
Study selection
We selected the studies that met the following criteria: (i) Observational studies with propensity score matching or clinical trials comparing TAVR and SAVR in patients with severe aortic stenosis or failed aortic bioprostheses; (ii) intermediate to high surgical risk defined as such by the authors or an STS score above 4% or a logistic EuroSCORE above 10% in both treatment arms; studies including inoperable patients were excluded; (iii) sample size per group (TAVR or SAVR) of at least 20 patients; (iv) studies that had to report at least one of the following events: (a) early events (30 days post-procedure or in-hospital): death, major stroke, major or life-threatening bleeding, vascular complications, acute kidney injury (AKI) or pacemaker implantation; (b) late events (follow-up > 12 months): death or major stroke and (c) haemodynamic findings: mean trans-prosthetic gradients or more than mild RAR and (v) similar risk profiles of TAVR and SAVR groups: differences of STS score or EuroSCORE had to be lower than 1% or 5%, respectively.
When we found different manuscripts reporting results at different times for the follow-up of the same cohort, information was only extracted from a single study: [1] For analyses of RAR or trans-prosthetic gradients, we selected the manuscript with the largest sample of patients in whom echocardiographic assessment had been made, to minimize survival bias. [2] For the analysis of post-procedure mortality or risk of stroke, we included only the earliest studies. [3] Regarding long-term (>1 year) events, manuscripts with the longest follow-up were selected.
Events and data extraction
The primary events were early (30 days or in-hospital) and longterm (>1 year) all-cause death and major stroke. We also compared the risk of early AKI, pacemaker implantation, vascular complications and major or life-threatening bleeding. Clinical events were evaluated according to the VARC-2 criteria [9] . Finally, we analysed two echocardiographic findings: greater than mild RAR (defined as moderate or severe aortic regurgitation or grade 3 or 4 on a maximum of 4) and mean trans-prosthetic gradients.
For propensity score matched studies, raw and adjusted data were collected, but only the latest were used to calculate the pooled estimates.
Additional information was extracted from the studies: authors, publication date, type of study, logistic EuroSCORE of each group, sample size, incidence of events per treatment arm, transcatheter approach, TAVR prosthesis manufacturer and model and duration of follow-up. Two independent researchers analysed each study, and disagreements were resolved by consensus.
The quality of each study was measured according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group recommendations [10] .
Statistical analyses
Study-specific estimates were combined using inverse varianceweighted averages of logarithmic odds ratios (ORs) and relative risks (RRs) in random-effects models. Between-study heterogeneity was analysed by means of I 2 (25% was mild, 50% moderate and 75% high) and the Q test (P < 0.10 was consistent with significant heterogeneity). To assess the differences of the transprosthetic gradients, the combined mean of the differences in the gradients was calculated with a random effects model and expressed with its corresponding 95% confidence interval (CI). Sensitivity analyses were performed according to the type of study, transcatheter device, surgical risk profile, antegrade/retrograde transcatheter approach or sutureless aortic valve replacement. Forest plots were used to illustrate the pooled estimates. Funnel plots represented publication bias and heterogeneity. Statistical analyses were performed using Stata for Mac OS, version 13.0 (StataCorp LP, Texas, USA).
RESULTS
We identified 45 studies (Fig. 1) [11] [12] [13] [14] [15] . In addition, we found the manuscripts reporting the 5-year follow-up of the Placement of Aortic Transcatheter Valves (PARTNER) trial [16] , the 3-year follow-up of the CoreValve High Risk Study Clinical Trial [17] and the 2-year follow-up of the Nordic Aortic Valve Intervention (NOTION) trial [18] . Finally, 37 observational studies with propensity score matching were also included (see Supplementary Material for references). Two randomized controlled trials (RCT) enrolled high-risk patients [11, 13] ; three recruited intermediate-risk patients [12, 14, 15] . Twenty-six observational studies included high-risk patients exclusively, and 11 enrolled intermediate-risk patients.
Early mortality
In 40 studies, early all-cause mortality was reported. Five clinical trials and 35 observational studies with n = 19 694 patients were included. In the pooled analysis, no significant differences were detected between TAVR and SAVR: OR = 1.11 (95% CI 0.89-1.39), P = 0.355, I 2 = 0%. We did not find any statistically significant differences between the two groups in RCT or observational studies (OR = 0.8, 95% CI 0.58-1.11 and OR = 1.19, 95% CI 0.93-1.53, respectively) (Fig. 2) .
In addition, we performed a sensitivity analysis to detect possible variations depending on different features of the studies (see Supplementary Table 2) . We did detect an increase in early mortality for TAVR when we performed a meta-comparison between TAVR and sutureless aortic valve replacement (SuAVR) (OR = 2.23, 95% CI 1.22-4.02).
Long-term mortality
We identified 17 studies (n = 8093) that analysed mortality over a follow-up period longer than 1 year. The pooled analysis (Fig. 3) did not demonstrate any statistically significant difference in the risk of long-term mortality when comparing TAVR versus SAVR: RR = 0.91 (95% CI 0.78-1.05), P = 0.194; I 2 = 0%. In RCT (n = 4), TAVR and SAVR had similar risks for long-term mortality (RR = 0.93, 95% CI 0.84-1.04); the findings were similar in observational studies (n = 13) (RR = 0.91, 95% CI 0.7-1.19). Sensitivity analyses and funnel plots are shown in Supplementary  Table 3 .
Major stroke
Pooled analysis of 31 studies (representing 15 375 patients) (Fig.  4) Ten studies compared the risk of long-term stroke (n = 8226) (Fig. 5) . We found no significant differences between TAVR and SAVR: RR = 0.78 (95% CI 0.56-1.07), P = 0.116, I 2 = 0%. Again, there was no difference based on the design of the study: RCT (n = 4): RR = 0.92 (95% CI 0.71-1.17); observational studies (n = 6): RR = 0.66 (95% CI 0.36-1.21). Sensitivity analyses are shown in Supplementary Table 5 .
Other clinical events
The pooled analysis of 21 studies (n = 11 073 patients) demonstrated a lower risk of major or life-threatening bleeding with TAVR compared with SAVR: OR= 0.42 (95% CI 0.25-0.69), P = 0.001, I 2 = 0% ( Supplementary Fig. 1 ). Interestingly, the risk was not different between TAVR and SuAVR (OR = 0.78, 95% CI 0. Table 6 ). Similarly, the risk for postprocedure AKI with TAVR was half that with SAVR in a metacomparison of 19 studies (n = 9643): OR= 0.51 (95% CI 0.35-0.74), P < 0.001, I 2 = 6.13% (See Supplementary Fig. 2 and Table 7 .)
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On the other hand, pooled analyses demonstrated that patients who had TAVR were at higher risk for vascular complications (n = 17, 12 570 patients, OR= 4.88 (95% CI 2.84-8.39), P < 0.001, I 2 = 0.52% (see Supplementary Fig. 3 and Table 8 ) and 
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pacemaker implantation (28 studies, n = 14 655, OR = 2.31 (95% CI 1.73-3.08), P < 0.001, I 2 = 21%) (see Supplementary Fig. 4 and Table 9 ).
Haemodynamic performance
The adjusted analysis of 22 studies (n = 9290) revealed that TAVR patients were at a significantly higher risk of moderate or severe RAR (OR = 6.83, 95% CI 4.87-9.6, P < 0.001, I 2 = 0%) (see Supplementary Fig. 5 ). This finding was consistent across all variables considered in the sensitivity analysis, including RCT, observational studies, patient risk or type of transcatheter device. (See Supplementary Table 10.) In contrast, TAVR prostheses had lower mean trans-prosthetic gradients compared with SAVR (n = 17, 8630 patients, pooled mean of gradients difference = -2.4 mmHg, 95% CI -3.27 to -1.53, P < 0.001, I 2 = 0%). (See Supplementary Fig. 6 and Table 11 .)
Funnel plots for each event are shown in Supplementary Figs.  7-15 . No significant publication biases were detected.
DISCUSSION
Conventional aortic valve surgery has evolved in recent decades, extending its indications to increasingly elderly and higher risk patients, while decreasing mortality and the incidence of stroke [19, 20] . However, until the last decade, up to a third of patients with indications for SVAR were rejected for such an intervention. The most frequent explanation for this rejection was a perception by the referral doctors of a high surgical risk [21] . TAVR represented a revolutionary therapy for poor surgical candidates and substantially changed the paradigm of the invasive treatment of aortic valve disease.
The benefits of TAVR over medical treatment in terms of life expectancy and quality of life for patients who have been refused for surgery are well known [22] . However, among patients at high or intermediate surgical risk, comparisons between SAVR and TAVR have not been consistent. Until now, the CoreValve US Pivotal Trial [13] was the only RCT that has detected a significant reduction in mortality (14.2% vs 19.1%, P = 0.04) for TAVR vs SAVR. None of the other four RCT [11, 12, 14, 15] reported significant differences. In parallel, results from observational studies have not been consistent. Some have detected an increased mortality in TAVR or SAVR, and most have not found significant differences. In our meta-analysis, we did not detect significant or clinically relevant differences in either early or late mortality rates between TAVR and SAVR. Furthermore, this relationship was similar across different subgroups. Gargiulo et al. [23] reported a meta-comparison of 20 studies (n = 5505) on long-term mortality. They found similar risks for TAVR and SAVR (OR = 0.96, 95% CI 0.81-1.14, P = 0.644, I 2 = 39%). Biondi-Zoccai et al. [24] compared mid-term mortality between SAVR and TAVR in a network metaanalysis that included four clinical trials and did not find any difference irrespective of the transcatheter approach. Finally, Siontis et al. [25] recently performed a meta-analysis of four RCT. In this study, the authors detected a lower mortality rate with TAVR (HR = 0.87, 0.76-0.99, P = 0.038), whereas we did not (RR = 0.93, 95% CI 0.84-1.04). This difference might be explained by the fact that Siontis et al. included manuscripts with a maximum follow-up of 2 years and estimated HR instead of RR.
Randomized control trials have reported different results for the incidence of major stroke for high-(8.1-11.8%) [11, 12] and intermediate-risk patients (2.8-5.9%) [13] [14] [15] after TAVR or SAVR. None of them detected any statistically significant difference between the two approaches. The present meta-analysis showed similar risks for early and long-term major stroke. Improvements both in SAVR and TAVR are being adopted to reduce the risk of stroke. Recently, the Claret Embolic Protection and TAVI (CLEAN-TAVI) trial [26] demonstrated the reduction of cerebral embolization with the Claret Montage Dual Filter System (Claret Medical Inc., Santa Rosa, CO, USA). On the other hand, a new sutureless aortic prosthesis may reduce the risk of embolization by minimizing the manipulation of the aortic root and annulus.
In this meta-analysis, the risks of AKI and major bleeding after TAVR were half those after SAVR. On the other hand, vascular complications or the need for pacemaker implantation increased by 2-and 5-fold, respectively. In a sensitivity analysis, we found that patients undergoing SuAVR had similar risks of major bleeding, AKI or pacemaker implantation compared with those undergoing TAVR. The reduced risk of bleeding or renal failure can be explained by the fact that most SuAVR are minimally invasive procedures, with limited wound bleeding, need for transfusion, inflammatory response and so forth. SuAVR are implanted by balloon inflation or self-expandable nitinol stents, just as with TAVR. Both mechanisms are known to increase the risk of atrioventricular block [27] . Nonetheless, these findings must be taken cautiously because this subgroup analysis included observational studies exclusively.
The incidence of moderate to severe RAR was significantly higher with TAVR. A sensitivity analysis showed that the residual AR in the TAVR group was more frequent regardless of the study design, the risk profile of the patients or the access site for TAVR. The impact of RAR on the prognosis of patients undergoing TAVR has been studied extensively. Urena et al. [28] showed that moderate to severe residual AR increased the risk of death from heart failure (HR = 2.79, 95% CI 1.82-4.27) in a sample of 3726 patients. The analysis of the effects of RAR in the cohort of TAVR patients in the PARTNER study found, among patients with moderate or severe residual AR, a 1-year mortality rate of 35.1% and an incidence of hospital readmission of 31.3%. Both mild (HR = 1.37, 95% CI 1.14-1.9) and moderate to severe RAR Figure 5 : Inverse variance random-effects RR and 95% CI for late stroke stratified by study design. RCT: randomized clinical trial; PSM: propensity score matched (HR = 2.18, 95% CI 1.57-3.02) were also independent risk factors for poor mid-term survival [29] .
We detected a statistically significant reduction in the mean gradients in TAVR prostheses compared with SAVR prostheses (-2.4 mmHg, 95% CI -3.27 to -1.53, P < 0.001, I 2 = 0%). This difference could be explained by the design of the prostheses and the infra-annular expansion in the LV outflow tract. Though the mean difference between the trans-prosthetic gradients might seem small, recent investigations suggest it could have prognostic implications: Pibarot et al. [30] detected a significant reduction in prosthesis-patient mismatch among TAVR patients in comparison to SAVR patients in the PARTNER trial (46.4% vs 60%, P < 0.001). Despite the controversy over identifying the impact of permanent pacemakers on survival, most surgeons tend not to be aggressive with aortic root enlargement procedures and placing larger valves, especially in high-risk patients.
We still lack crucial information to further assess possible drawbacks or benefits of TAVR and SAVR, such as the durability of TAVR prostheses, the impact of new sutureless and transcatheter bioprosthesis designs, delivery systems and the widespread use of minimally invasive approaches.
In short, mortality and the risk of stroke are similar with TAVR and SAVR. TAVR is associated with a significant increase in RAR, vascular complications and the need for pacemaker implantation. On the other hand, SAVR increases the risk of major bleeding, AKI and a slightly worse haemodynamic performance. Considering these findings, it seems that the decision to use one strategy or the other still must rely on careful patient evaluation and the criteria of local heart teams.
LIMITATIONS
The baseline characteristics for the two groups could not be compared entirely because of the meta-analytic nature of the study. There is always potential for publication bias. Many of these studies were small, with limited ability to assess outcomes. Some of these studies may have been underpowered. The overall follow-up period was short, especially for intermediate-risk patients, which is why it is crucial to investigate other outcomes such as durability of the prostheses. Only a few RCT were available for subgroup analysis. We were unable to measure procedure-specific outcomes between trans-femoral, transapical or subclavian TAVR and SAVR. The use of old-generation prostheses in some studies may limit the validity of the findings in the current meta-analysis. Further comparisons will have to be performed when more data on Sapien 3, Lotus and others are available.
Although the relationship between TAVR and RAR is strong, there is a possible bias and lack of agreement in the diagnosis of RAR, because its assessment is highly observer dependent. Besides, given the survival bias and the high number of patients lost to follow-up, we analysed only early RAR. Other outcomes should be contemplated in further meta-analyses such as prosthesis durability, causes of mortality, atrial fibrillation, costs and prosthetic endocarditis.
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